Oxford BioTherapeutics (OBT) has appointed Dr Michael Moore non-executive chairman. He joins the company following five years spent at UK …
Roche is set to pay $160 million (£315 million) to buy UK biotech company Piramed, a move which will further …
Piramed and Domainex are among the cutting-edge companies which have been recognised as the best of the UKs biotech sector.UK …
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact

